Nurix Therapeutics, Inc. (NRIX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs October 22, 2025 8:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Paula O'Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer Johannes Van Houte - Chief Financial Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Gil Blum - Needham & Company, LLC, Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Joseph Catanzaro Brian Abrahams - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Alexander Barenklau - Barclays Bank PLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Arthur Sands CEO, President & Director Good morning, and welcome to the Nurix Therapeutics Conference Call.
Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones
Nurix Therapeutics maintains a Strong Buy rating, driven by promising progress with its oral BTK degrader bexobrutideg for relapsed/refractory CLL. NRIX plans to initiate a pivotal single-arm phase 2 study in 2H 2025, potentially enabling Accelerated Approval based on strong phase 1a data (80.9% ORR). Future expansion includes a phase 3 randomized trial and combinations to target 1st- and 2nd-line CLL, addressing a multibillion-dollar market opportunity.
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.67 per share a year ago.
Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX ) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participants Robert Burns - H.C.
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors
NRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pharma like Gilead, Sanofi, and Pfizer to expand its promising targeted protein degradation IP franchise. I estimate their cash and marketable securities provide roughly 1.9 years of cash runway based on NRIX's Q1 figures. This is a risk worth considering for long-term investors.
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Nurix Therapeutics (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago.
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
Nurix Therapeutics, Inc. (NRIX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
